TickerStat.comEloxx Pharmaceuticals annual return on equity
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2015
2016
2016
2017
2017
2018
2019
2020
2021
2022
Eloxx Pharmaceuticals Return on Equity (ROE) Growth & History (ELOX)
Eloxx Pharmaceuticals's return on equity was −615.23% for fiscal 2022.
View full Eloxx Pharmaceuticals company overviewEloxx Pharmaceuticals annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2022 | 2022-12-31 | −615.23% | −206.04 pp |
| 2021 | 2021-12-31 | −409.19% | −260.29 pp |
| 2020 | 2020-12-31 | −148.90% | −20.31 pp |
| 2019 | 2019-12-31 | −128.59% | +18.24 pp |
| 2018 | 2018-12-31 | −146.83% | +44.01 pp |
| 2017 · Dec 31 | 2017-12-31 | −190.84% | +190.04 pp |
| 2017 · Jun 30 | 2017-06-30 | −782.65% | −464.88 pp |
| 2016 · Dec 31 | 2016-12-31 | −380.88% | −281.31 pp |
| 2016 · Jun 30 | 2016-06-30 | −317.77% | −226.81 pp |
| 2015 · Dec 31 | 2015-12-31 | −99.57% | — |
| 2015 · Jun 30 | 2015-06-30 | −90.97% | −31.98 pp |
| 2014 | 2014-06-30 | −58.99% | +110.16 pp |
| 2013 | 2013-06-30 | −169.15% | −42.03 pp |
| 2012 | 2012-06-30 | −127.12% | −10.80 pp |
| 2011 | 2011-06-30 | −116.32% | +79.79 pp |
| 2010 | 2010-06-30 | −196.11% | −122.23 pp |
| 2009 | 2009-06-30 | −73.88% | −0.40 pp |
| 2008 | 2008-06-30 | −73.48% | +41.80 pp |
| 2007 | 2007-06-30 | −115.28% | −37.66 pp |
| 2006 | 2006-06-30 | −77.62% | −19.89 pp |
| 2005 | 2005-06-30 | −57.73% | +40.51 pp |
| 2004 | 2004-06-30 | −98.24% | −25.54 pp |
| 2003 | 2003-06-30 | −72.70% | +59.28 pp |
| 2002 | 2002-06-30 | −131.98% | +178.10 pp |
| 2001 | 2001-06-30 | −310.08% | −34.73 pp |
| 2000 | 2000-06-30 | −275.35% | — |
Eloxx Pharmaceuticals quarterly return on equity
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q4.15
Q1.16
Q4.16
Q1.17
Q4.16
Q1.17
Q4.17
Q1.18
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q1.23
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −23.18% | — |
| Q1 2023 | 2023-03-31 | −221.20% | −152.98 pp |
| Q2 2022 | 2022-06-30 | −157.33% | +8.87 pp |
| Q1 2022 | 2022-03-31 | −68.21% | +65.75 pp |
| Q4 2021 | 2021-12-31 | −43.66% | +4.76 pp |
| Q3 2021 | 2021-09-30 | −26.85% | +10.57 pp |
| Q2 2021 | 2021-06-30 | −166.19% | −132.31 pp |
| Q1 2021 | 2021-03-31 | −133.96% | −89.31 pp |
| Q4 2020 | 2020-12-31 | −48.42% | −19.85 pp |
| Q3 2020 | 2020-09-30 | −37.42% | −11.78 pp |
| Q2 2020 | 2020-06-30 | −33.89% | −1.66 pp |
| Q1 2020 | 2020-03-31 | −44.65% | −13.83 pp |
| Q4 2019 | 2019-12-31 | −28.57% | +1.16 pp |
| Q3 2019 | 2019-09-30 | −25.63% | −5.59 pp |
| Q2 2019 | 2019-06-30 | −32.23% | +4.29 pp |
| Q1 2019 | 2019-03-31 | −30.82% | +18.46 pp |
| Q4 2018 | 2018-12-31 | −29.73% | +56.19 pp |
| Q3 2018 | 2018-09-30 | −20.04% | +172.98 pp |
| Q2 2018 | 2018-06-30 | −36.52% | +187.91 pp |
| Q1 2018 · Mar 31 | 2018-03-31 | −49.28% | +118.37 pp |
| Q4 2017 | 2017-12-31 | −85.91% | −48.62 pp |
| Q1 2018 · Sep 30 | 2017-09-30 | −193.03% | −170.22 pp |
| Q4 2017 | 2017-06-30 | −224.43% | −201.83 pp |
| Q1 2017 · Mar 31 | 2017-03-31 | −167.65% | −69.67 pp |
| Q4 2016 | 2016-12-31 | −37.29% | +21.35 pp |
| Q1 2017 · Sep 30 | 2016-09-30 | −22.81% | −21.35 pp |
| Q4 2016 | 2016-06-30 | −22.59% | −14.85 pp |
| Q1 2016 · Mar 31 | 2016-03-31 | −97.98% | −87.38 pp |
| Q4 2015 | 2015-12-31 | −58.65% | +3.89 pp |
| Q1 2016 · Sep 30 | 2015-09-30 | −1.46% | +19.31 pp |
| Q4 2015 | 2015-06-30 | −7.74% | +11.97 pp |
| Q3 2015 | 2015-03-31 | −10.60% | +13.90 pp |
| Q2 2015 | 2014-12-31 | −62.53% | −29.60 pp |
| Q1 2015 | 2014-09-30 | −20.77% | +39.68 pp |
| Q4 2014 | 2014-06-30 | −19.71% | +34.70 pp |
| Q3 2014 | 2014-03-31 | −24.50% | +9.70 pp |
| Q2 2014 | 2013-12-31 | −32.93% | +27.39 pp |
| Q1 2014 | 2013-09-30 | −60.45% | +8.12 pp |
| Q4 2013 | 2013-06-30 | −54.40% | −18.66 pp |
| Q3 2013 | 2013-03-31 | −34.20% | −5.66 pp |
| Q2 2013 | 2012-12-31 | −60.32% | −15.17 pp |
| Q1 2013 | 2012-09-30 | −68.57% | −43.98 pp |
| Q4 2012 | 2012-06-30 | −35.74% | — |
| Q3 2012 | 2012-03-31 | −28.54% | — |
| Q2 2012 | 2011-12-31 | −45.15% | — |
| Q1 2012 | 2011-09-30 | −24.59% | — |
Eloxx Pharmaceuticals return on equity trends
Over the last five fiscal years, Eloxx Pharmaceuticals's return on equity decreased from −190.84% to −615.23%, a change of −424.39 percentage points. The latest reported quarter, Q2 2026, shows −23.18%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eloxx Pharmaceuticals source filings ↗Community posts
Eloxx doses first patients in mid-stage Alport syndrome trial
Eloxx Pharmaceuticals ($ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for Alport syndrome caused by nonsense mutations. The trial plans to enroll 24 patients with relevant mutations in the COL4A3, COL4A4 or COL4 ...